<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01335997</url>
  </required_header>
  <id_info>
    <org_study_id>0524B-143</org_study_id>
    <secondary_id>2011-001007-12</secondary_id>
    <nct_id>NCT01335997</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Extended-Release Niacin/ Laropiprant/Simvastatin Tablets in Participants With Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-143)</brief_title>
  <official_title>A Phase III Multicenter, Double-Blind, Crossover Design Study to Evaluate Lipid-Altering Efficacy and Safety of 1 g/10 mg Extended-Release Niacin/Laropiprant/Simvastatin Combination Tablets in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being done to find out if tablets containing extended release (ER) niacin,
      laropiprant, and simvastatin (ERN/LRPT/SIM) are as effective as tablets containing ER niacin
      and laropiprant taken with simvastatin tablets (ERN/LRPT + SIM) for lowering high cholesterol
      and high lipid levels in the blood. The primary hypothesis is that ERN/LRPT/SIM 2 g /20 mg is
      equivalent to ERN/LRPT 2 g coadministered with simvastatin 20 mg in reducing low-density
      lipoprotein cholestrol (LDL-C).
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Business Reasons
  </why_stopped>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) Blood Levels</measure>
    <time_frame>Baseline and Week 12 and Week 20</time_frame>
    <description>Due to study termination caused by the decision to stop the development of the combination tablet, sufficient data were not available to perform the planned efficacy analysis, which is based on the cross-over data collected in period II and III.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) Blood Levels</measure>
    <time_frame>Baseline and Week 12 and Week 20</time_frame>
    <description>Due to study termination caused by the decision to stop the development of the combination tablet, sufficient data were not available to perform the planned efficacy analysis, which is based on the cross-over data collected in period II and III.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1139</enrollment>
  <condition>Primary Hypercholesterolemia</condition>
  <condition>Mixed Dyslipidemia</condition>
  <arm_group>
    <arm_group_label>ERN/LRPT/SIM → ERN/LRPT+SIM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Weeks 0-4 (Period 1): Participants will take ERN/LRPT/SIM 1 g/10 mg and SIM-matching placebo tablets daily; Weeks 5-12 (Period 2): Participants will be advanced to ERN/LRPT/SIM 2 g/20 mg and SIM-matching placebo tablets daily; Weeks 13-20 (Period III): Participants will crossover to ERN/LRPT 2 g + SIM 20 mg coadministration treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ERN/LRPT+SIM → ERN/LRPT/SIM</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Weeks 0-4 (Period I): Participants will take ERN/LRPT co-administered with SIM (ERN/LRPT 1g + SIM 10 mg tablets) daily; Weeks 5-12 (Period II): Participants will be advanced to ERN/LRPT 2 g + SIM 20 mg daily; Weeks 13-20 (Period III): Participants will crossover to the ERN/LRPT/SIM 2 g/20 mg combination treatment and SIM-matching placebo tablets.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ER niacin/laropiprant (ERN/LRPT)</intervention_name>
    <description>ER niacin 1 g/laropiprant 20 mg oral tablet taken once daily</description>
    <arm_group_label>ERN/LRPT/SIM → ERN/LRPT+SIM</arm_group_label>
    <arm_group_label>ERN/LRPT+SIM → ERN/LRPT/SIM</arm_group_label>
    <other_name>MK-0524B</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ER niacin/laropiprant/simvastatin (ERN/LRPT/SIM)</intervention_name>
    <description>ER niacin 1 g/laropiprant 20 mg/simvastatin 10 mg oral tablet taken once daily</description>
    <arm_group_label>ERN/LRPT/SIM → ERN/LRPT+SIM</arm_group_label>
    <arm_group_label>ERN/LRPT+SIM → ERN/LRPT/SIM</arm_group_label>
    <other_name>MK-0524A, Tredaptive™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin (SIM)</intervention_name>
    <description>Simvastatin 10 mg oral tablet taken once daily</description>
    <arm_group_label>ERN/LRPT/SIM → ERN/LRPT+SIM</arm_group_label>
    <arm_group_label>ERN/LRPT+SIM → ERN/LRPT/SIM</arm_group_label>
    <other_name>Zocor®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Run-In</intervention_name>
    <description>Placebo matches both ER niacin 1 g/laropiprant 20 mg oral tablet and ER niacin 1 g/laropiprant 20 mg/simvastatin 10 mg oral tablet; placebo is taken once daily</description>
    <arm_group_label>ERN/LRPT/SIM → ERN/LRPT+SIM</arm_group_label>
    <arm_group_label>ERN/LRPT+SIM → ERN/LRPT/SIM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SIM-matching placebo</intervention_name>
    <description>Placebo for simvastatin 10 mg oral tablet taken once daily</description>
    <arm_group_label>ERN/LRPT/SIM → ERN/LRPT+SIM</arm_group_label>
    <arm_group_label>ERN/LRPT+SIM → ERN/LRPT/SIM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Has a history of primary hypercholesterolemia or mixed dyslipidemia and meets LDL-C
             and triglyceride criteria.

          -  Is high risk coronary heart disease (CHD) and has LDL-C ≤190 mg/dL (≤4.91 mmol/L).

          -  Is not high risk CHD and has LDL-C ≤240 mg/dL (≤6.21 mmol/L).

        Exclusion criteria:

          -  Is pregnant or breast-feeding, or expecting to conceive or donate eggs or sperm during
             the study.

          -  Has a history of malignancy within ≤5 years, except for adequately treated basal cell
             or squamous cell skin cancer or in situ cervical cancer.

          -  Consumes more than 3 alcoholic drinks per day (14 per week).

          -  Is a high risk CHD patient on lipid modifying therapy (LMT).

          -  Is on any LMT with equivalent or greater LDL-C-lowering efficacy than simvastatin 40
             mg.

          -  Has Type 1 or Type 2 diabetes mellitus that is poorly controlled, or on statin
             therapy.

          -  Currently engages in vigorous exercise or is on an aggressive diet regimen.

          -  Has uncontrolled endocrine or metabolic disease, uncontrolled gout, kidney or hepatic
             disease, heart failure, recent peptic ulcer disease, hypersensitivity or allergic
             reaction to niacin or simvastatin, recent heart attack, stroke or heart surgery.

          -  Is human immunodeficiency virus (HIV) positive.

          -  Has taken niacin &gt;50 mg/day, bile-acid sequestrants,
             3-hydroxy-3-methylglutaryl-coenzyme A(HMG-CoA) reductase inhibitors, ezetimibe,
             Cholestin™ [red yeast rice] and other red yeast products within 6 weeks, or fibrates
             within 8 weeks of randomization visit (Visit 3).

        Note: Fish oils, phytosterol margarines and other non-prescribed therapies are allowed
        provided participant has been on a stable dose for 6 weeks prior to Visit 2 and agrees to
        remain on this dose for the duration of the study.

          -  Is currently receiving cyclical hormonal contraceptives or intermittent use of hormone
             replacement therapies (HRTs) (e.g., estradiol, medroxyprogesterone, progesterone).
             Note: Participants who have been on a stable dose of non-cyclical HRT or hormonal
             contraceptive for greater than 6 weeks prior to Visit 1 are eligible if they agree to
             remain on the same regimen for the duration of the study.

          -  Is taking prohibited medications such as systemic corticosteroids, potent inhibitors
             of Cytochrome P450 3A4 (CYP3A4), cyclosporine, danazol, or fusidic acid.

          -  Consumes &gt;1 quart of grapefruit juice/day.

          -  Requires warfarin treatment and has not been on a stable dose with a stable
             International Normalized Ratio (INR) for at least 6 weeks prior to Visit 1.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Mexico</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2011</study_first_submitted>
  <study_first_submitted_qc>April 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2011</study_first_posted>
  <results_first_submitted>January 13, 2016</results_first_submitted>
  <results_first_submitted_qc>May 12, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 21, 2016</results_first_posted>
  <last_update_submitted>March 6, 2017</last_update_submitted>
  <last_update_submitted_qc>March 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Low-density lipoprotein</keyword>
  <keyword>LDL</keyword>
  <keyword>High-density lipoprotein</keyword>
  <keyword>HDL</keyword>
  <keyword>Niacin</keyword>
  <keyword>Lipid modifying therapy</keyword>
  <keyword>Cholesterol</keyword>
  <keyword>High cholesterol</keyword>
  <keyword>Triglycerides</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
  </intervention_browse>
  <study_docs>
    <study_doc>
      <doc_type>CSR Synsopsi Link</doc_type>
      <doc_url>http://www.merck.com/clinical-trials/study.html?id=0524B-143&amp;kw=0524B-143&amp;tab=access</doc_url>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Sequence 1 (randomized) = 577; Sequence 2 (randomized) = 562</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>ERN/LRPT/SIM → ERN/LRPT+SIM (Sequence 1)</title>
          <description>Study drug was administered as extended-release niacin/laropiprant/simvastatin combination (ERN/LRPT/SIM) during Period I and II for 12 weeks and extended-release niacin/laropiprant (ERN/LRPT) + simvastatin (SIM) during Period III for 8 weeks.</description>
        </group>
        <group group_id="P2">
          <title>ERN/LRPT+SIM → ERN/LRPT/SIM (Sequence 2)</title>
          <description>Study drug was co-administered as extended-release niacin/laropiprant (ERN/LRPT) + simvastatin (SIM) (ERN/LRPT + SIM) during Periods I and II for 12 weeks and extended-release niacin/laropiprant/simvastatin combination (ERN/LRPT/SIM) during Period III for 8 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period I and II</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="577"/>
                <participants group_id="P2" count="562"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="84"/>
                <participants group_id="P2" count="83"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="493"/>
                <participants group_id="P2" count="479"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="63"/>
                <participants group_id="P2" count="43"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Noncompliance with Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study Terminated by Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="406"/>
                <participants group_id="P2" count="415"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period III</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="84"/>
                <participants group_id="P2" count="83"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="78"/>
                <participants group_id="P2" count="79"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study Terminated by Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="77"/>
                <participants group_id="P2" count="76"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ERN/LRPT/SIM → ERN/LRPT+SIM (Sequence 1)</title>
          <description>Study drug was administered as extended-release niacin/laropiprant/simvastatin combination (ERN/LRPT/SIM) during Period I and II for 12 weeks and extended-release niacin/laropiprant (ERN/LRPT) + simvastatin (SIM) during Period III for 8 weeks.</description>
        </group>
        <group group_id="B2">
          <title>ERN/LRPT+SIM → ERN/LRPT/SIM (Sequence 2)</title>
          <description>Study drug was co-administered as extended-release niacin/laropiprant (ERN/LRPT) + simvastatin (SIM) (ERN/LRPT + SIM) during Periods I and II for 12 weeks and extended-release niacin/laropiprant/simvastatin combination (ERN/LRPT/SIM) during Period III for 8 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="577"/>
            <count group_id="B2" value="562"/>
            <count group_id="B3" value="1139"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.2" spread="10.44"/>
                    <measurement group_id="B2" value="56.4" spread="10.44"/>
                    <measurement group_id="B3" value="56.3" spread="10.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="345"/>
                    <measurement group_id="B2" value="332"/>
                    <measurement group_id="B3" value="677"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="232"/>
                    <measurement group_id="B2" value="230"/>
                    <measurement group_id="B3" value="462"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) Blood Levels</title>
        <description>Due to study termination caused by the decision to stop the development of the combination tablet, sufficient data were not available to perform the planned efficacy analysis, which is based on the cross-over data collected in period II and III.</description>
        <time_frame>Baseline and Week 12 and Week 20</time_frame>
        <population>Completers Population - participants that completed the study, have respective endpoint data available at baseline, end of period II and end of period III and were not off study drug more than 3 days prior to their period II and period III observations.</population>
        <group_list>
          <group group_id="O1">
            <title>ERN/LRPT/SIM → ERN/LRPT+SIM (Sequence 1)</title>
            <description>Study drug was administered as extended-release niacin/laropiprant/simvastatin combination (ERN/LRPT/SIM) during Period I and II for 12 weeks and extended-release niacin/laropiprant (ERN/LRPT) + simvastatin (SIM) during Period III for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>ERN/LRPT+SIM → ERN/LRPT/SIM (Sequence 2)</title>
            <description>Study drug was co-administered as extended-release niacin/laropiprant (ERN/LRPT) + simvastatin (SIM) (ERN/LRPT + SIM) during Periods I and II for 12 weeks and extended-release niacin/laropiprant/simvastatin combination (ERN/LRPT/SIM) during Period III for 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) Blood Levels</title>
          <description>Due to study termination caused by the decision to stop the development of the combination tablet, sufficient data were not available to perform the planned efficacy analysis, which is based on the cross-over data collected in period II and III.</description>
          <population>Completers Population - participants that completed the study, have respective endpoint data available at baseline, end of period II and end of period III and were not off study drug more than 3 days prior to their period II and period III observations.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) Blood Levels</title>
        <description>Due to study termination caused by the decision to stop the development of the combination tablet, sufficient data were not available to perform the planned efficacy analysis, which is based on the cross-over data collected in period II and III.</description>
        <time_frame>Baseline and Week 12 and Week 20</time_frame>
        <population>Completers Population - participants that completed the study, have respective endpoint data available at baseline, end of period II and end of period III and were not off study drug more than 3 days prior to their period II and period III observations.</population>
        <group_list>
          <group group_id="O1">
            <title>ERN/LRPT/SIM → ERN/LRPT+SIM (Sequence 1)</title>
            <description>Study drug was administered as extended-release niacin/laropiprant/simvastatin combination (ERN/LRPT/SIM) during Period I and II for 12 weeks and extended-release niacin/laropiprant (ERN/LRPT) + simvastatin (SIM) during Period III for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>ERN/LRPT+SIM → ERN/LRPT/SIM (Sequence 2)</title>
            <description>Study drug was co-administered as extended-release niacin/laropiprant (ERN/LRPT) + simvastatin (SIM) (ERN/LRPT + SIM) during Periods I and II for 12 weeks and extended-release niacin/laropiprant/simvastatin combination (ERN/LRPT/SIM) during Period III for 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) Blood Levels</title>
          <description>Due to study termination caused by the decision to stop the development of the combination tablet, sufficient data were not available to perform the planned efficacy analysis, which is based on the cross-over data collected in period II and III.</description>
          <population>Completers Population - participants that completed the study, have respective endpoint data available at baseline, end of period II and end of period III and were not off study drug more than 3 days prior to their period II and period III observations.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 22 weeks, including 14 days after last dose of study drug (non-serious adverse events up to 20 weeks and serious adverse events up to 22 weeks)</time_frame>
      <desc>The All Participants as Treated (APaT) population consisted of all randomized participants who received at least one (1) dose of study treatment post-randomization. Participants were included in the treatment sequences corresponding to the study treatment they actually received.</desc>
      <group_list>
        <group group_id="E1">
          <title>Seq 1 (Periods I+II): ERN/LRPT/SIMVA → ERN/LRPT+SIMVA</title>
          <description>ERN/LRPT/SIMVA 1 g/10 mg for 4 weeks (Period I) followed by ERN/LRPT/SIMVA 2 g/20 mg for 8 weeks (Period II)</description>
        </group>
        <group group_id="E2">
          <title>Seq 2 (Periods I+II): ERN/LRPT+SIM → ERN/LRPT/SIM</title>
          <description>ERN/LRPT 1 g + SIMVA 10 mg for 4 weeks (Period I) followed by ERN/LRPT 2 g + SIMVA 20 mg for 8 weeks (Period II)</description>
        </group>
        <group group_id="E3">
          <title>Seq 1 (Period III): ERN/LRPT/SIMVA → ERN/LRPT+SIMVA</title>
          <description>ERN/LRPT 2 g + SIMVA 20 mg for 8 weeks (Period III)</description>
        </group>
        <group group_id="E4">
          <title>Seq 2 (Period III): ERN/LRPT+SIM → ERN/LRPT/SIM</title>
          <description>ERN/LRPT/SIMVA 2 g/20 mg for 8 weeks (Period III)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="567"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="554"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="567"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Arteriospasm coronary</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="567"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="567"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="567"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="567"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="567"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="567"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="567"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="567"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="567"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="567"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Thymoma malignant</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="567"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="567"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="567"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="567"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="567"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="567"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="567"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="567"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="567"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="554"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="103" subjects_at_risk="567"/>
                <counts group_id="E2" subjects_affected="95" subjects_at_risk="554"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="43" subjects_affected="39" subjects_at_risk="567"/>
                <counts group_id="E2" events="33" subjects_affected="29" subjects_at_risk="554"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="90" subjects_affected="78" subjects_at_risk="567"/>
                <counts group_id="E2" events="78" subjects_affected="72" subjects_at_risk="554"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study was terminated for business reasons.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

